The DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
A Specific Inhibitor of TGF-β Receptor Kinase, SB-431542, as a Potent Antitumor Agent for Human Cancers
Open accessAbstract
Small molecule inhibitors of signaling pathways have proven to be extremely useful for the development of therapeutic strategies for human cancers. Blocking the tumor-promoting effects of transforming growth factor-beta (TGF-beta) in advanced stage carcinogenesis provides a potentially interesting drug target for therapeutic intervention. Although very few TGF-beta receptor kinase inhibitors (TRKI) are now emerging in preclinical studies, nothing is known about how these inhibitors might regulate the tumor-suppressive or tumor-promoting effects of TGF-beta, or when these inhibitors might be useful for treatment during cancer progression. We have investigated the potential of TRKI in new therapeutic approaches in preclinical models. Here, we demonstrate that the TRKI, SB-431542, inhibits TGF-beta-induced transcription, gene expression, apoptosis, and growth suppression. We have observed that SB-431542 attenuates the tumor-promoting effects of TGF-beta, including TGF-beta-induced EMT, cell motility, migration and invasion, and vascular endothelial growth factor secretion in human cancer cell lines. Interestingly, SB-431542 induces anchorage independent growth of cells that are growth-inhibited by TGF-beta, whereas it reduces colony formation by cells that are growth-promoted by TGF-beta. However, SB-431542 has no effect on a cell line that failed to respond to TGF-beta. This represents a novel potential application of these inhibitors as therapeutic agents for human cancers with the goal of blocking tumor invasion, angiogenesis, and metastasis, when tumors are refractory to TGF-beta-induced tumor-suppressor functions but responsive to tumor-promoting effects of TGF-beta.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“JSH-23 and SB-431542 can suppress NF-κB and TGF-β1/Smad3 signaling pathways respectively and thus might inhibit platelet aggregation in endometriosis91,92.”
From Platelets induce increased estrogen production through NF-κB and TGF-β1 signaling pathways in endometriotic stromal cells (2020) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,571
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
TGF-β signalling from cell membrane to nucleus through SMAD proteins
Heldin, C., Miyazono, K., & ten Dijke, P. (1997) · Nature · doi:10.1038/37284 · Cited by 3,697
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Transcriptional control by the TGF‐β/Smad signaling system
Massagué, J., & Wotton, D. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1745 · Cited by 1,990
Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., & Hill, C. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.65 · Cited by 1,636
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1208 · Cited by 1,626
Bhowmick, N., Ghiassi, M., Bakin, A. V., Aakre, M., Lundquist, C., Engel, M., Arteaga, C., & Moses, H. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.27 · Cited by 1,087
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. J., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C., et al. (1999) · Nature Cell Biology · doi:10.1038/12971 · Cited by 911
TGF-β signaling: positive and negative effects on tumorigenesis
Wakefield, L. M. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00259-3 · Cited by 827
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., & Kang, A. H. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.251 · Cited by 777
Laping, N. J., Grygielko, E. T., Mathur, A., Butter, S., Bomberger, J. M., Tweed, C. W., Martin, W., Fornwald, J. A., Lehr, R. V., Harling, J. D., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.58 · Cited by 638
TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
Oft, M., Heider, K., & Beug, H. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00533-7 · Cited by 624
Smads as transcriptional co-modulators
Attisano, L., & Wrana, J. L. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00081-2 · Cited by 530
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S. T., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15234 · Cited by 522
Role of Transforming Growth Factor-beta Signaling in Cancer
de Caestecker, M. P. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.17.1388 · Cited by 521
Bakin, A. V., Rinehart, C., Tomlinson, A. K., & Arteaga, C. L. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.15.3193 · Cited by 429
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 411
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Ellenrieder, V., Hendler, S. F., Boeck, W., Seufferlein, T., Menke, A., Ruhland, C., Adler, G., & Gress, T. M. (2001) · PubMed · Cited by 361
Callahan, J. F., Burgess, J. L., Fornwald, J. A., Gaster, L. M., Harling, J. D., Harrington, F. P., Heer, J. P., Kwon, C., Lehr, R. V., Mathur, A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010493y · Cited by 309
Targeting the TGFβ signaling network in human neoplasia
Dumont, N., & Arteaga, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00135-1 · Cited by 243
Sheng, H., Shao, J., Dixon, D. A., Williams, C. S., Prescott, S. M., DuBois, R. N., & Beauchamp, R. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6628 · Cited by 196
Self-citationHjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F., & Rich, J. N. (2004) · PubMed · Cited by 192
Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X., & Rich, J. N. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.737.3.6 · Cited by 177
Watabe, T., Nishihara, A., Mishima, K., Yamashita, J. K., Shimizu, K., Miyazawa, K., Nishikawa, S., & Miyazono, K. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305147 · Cited by 176
Matsuyama, S., Iwadate, M., Kondo, M., Saitoh, M., Hanyu, A., Shimizu, K., Aburatani, H., Mishima, H. K., Imamura, T., Miyazono, K., et al. (2003) · PubMed · Cited by 142
Chemoinformatics – predicting the physicochemical properties of 'drug-like' molecules
Blake, J. F. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00062-2 · Cited by 137
Growth factors and transformation.
Roberts, A. B., & Sporn, M. B. (1986) · PubMed · Cited by 128
Diet diversity and gastric cancer
Vecchia, C. L., Muñoz, S. E., Braga, C., Fernández, E., & Decarli, A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970717)72:2 · Cited by 107
Osada, H., Tatematsu, Y., Masuda, A., Saito, T., Sugiyama, M., Yanagisawa, K., & Takahashi, T. (2001) · PubMed · Cited by 83
Signal Transduction of the TGF- Superfamily by Smad Proteins
Kawabata, M., & Miyazono, K. (1999) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022273 · Cited by 64
Wrana, J. L. (2000) · Science s STKE · doi:10.1126/stke.2000.23.re1 · Cited by 52
Flagged first, then by citations
4 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360
Tissue invasion and metastasis: Molecular, biological and clinical perspectives
Jiang, W. G., Sanders, A. J., Katoh, M., Ungefroren, H., Gieseler, F., Prince, M. E., Thompson, S. K., Zollo, M., Spano, D., Dhawan, P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.008 · Cited by 536
Spencer, M., Yao-Borengasser, A., Unal, R., Rasouli, N., Gurley, C. M., Zhu, B., Peterson, C. A., & Kern, P. A. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2010 · Cited by 439
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 394
Epithelial–mesenchymal transition and tumour invasion
Guarino, M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.011 · Cited by 375
Metadata
- Authors
- Halder, S. K., Beauchamp, R. D., & Datta, P. K.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Datta, Pran K.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 7
- Issue
- 5
- Pages
- 509-521
- ISSN
- 1476-5586 (ISSN-L)
- PMC
- PMC1501161
- OpenAlex
- W1990842005
- Cited by
- 288
- References
- 37
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 13 · 2023: 9 · 2022: 13 · 2021: 8 · 2020: 16 · 2019: 18 · 2018: 14 · 2017: 11 · 2016: 14 · 2015: 18 · 2014: 18 · 2013: 16 · 2012: 16
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neoplasia (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Research Institute
- GlaxoSmithKline
- Virginia Marine Resources Commission
- National Cancer Institute (R01CA095195, 5P50CA90949, R01CA95195, R01CA069457, CA-69457, P50CA090949)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK52334, R01DK052334)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- SB431542, TGF-beta, anticancer agents, epithelial-mesenchymal transition, tumor invasion, angiogenesis, metastasis, apoptosis, anchorage-independent growth, colony formation, cell motility, vascular endothelial growth factor, TGF-beta signaling
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Animals, Antineoplastic Agents, Benzamides, Cell Adhesion, Cell Line, Cell Movement, Dioxoles, Enzyme Inhibitors, Humans, Mink, Models, Biological, Neoplasm Invasiveness, Neoplasm Metastasis, Neovascularization, Pathologic, Time Factors, Transcription, Genetic, Blotting, Western, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Apoptosis, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Activin Receptors, Type I, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Immunoprecipitation, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
